Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

April 14, 2026 updated by: Seda Nur Kemer, Ondokuz Mayıs University

Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis

This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

22

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Progressive Multiple Sclerosis

Description

Inclusion Criteria:

  • Confirmed diagnosis of MS
  • Progressive type MS
  • Voluntary participation
  • Age between 18-60 years
  • Cooperative
  • EDSS score ≥ 5.5

Exclusion Criteria:

  • Presence of another neurological disorder
  • Change in medication within the last 3 months
  • Relapse within the last 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Progressive Multiple Sclerosis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Expanded Disability Status Scale (EDSS)
Time Frame: Baseline
The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.
Baseline
Standardized Mini-Mental Test
Time Frame: Baseline
The Standardized Mini-Mental Test (MMT/MMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.
Baseline
Symbol Digit Modalities Test
Time Frame: Baseline

The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination.

Score range: Typically 0 to ~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function
Baseline
Multiple Sclerosis Impact Scale (MSIS-29)
Time Frame: Baseline
Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)
Baseline
Glial Fibrillary Acidic Protein (GFAP)
Time Frame: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA)
Baseline
Neurofilament Light Chain (NfL)
Time Frame: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
Baseline
Vascular Endothelial Growth Factor (VEGF)
Time Frame: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ondokuz Mayıs University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 21, 2026

Primary Completion (Estimated)

April 30, 2026

Study Completion (Estimated)

May 5, 2026

Study Registration Dates

First Submitted

April 3, 2026

First Submitted That Met QC Criteria

April 14, 2026

First Posted (Actual)

April 17, 2026

Study Record Updates

Last Update Posted (Actual)

April 17, 2026

Last Update Submitted That Met QC Criteria

April 14, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025/426

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe